PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of pparresPPAR Research
 
PPAR Res. 2010; 2010: 703735.
Published online 2010 June 14. doi:  10.1155/2010/703735
PMCID: PMC2896859

Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of a steroid hormone receptor superfamily that responds to changes in lipid and glucose homeostasis. Peroxisomal proliferator-activated receptor subtype γ (PPARγ) has received much attention as the target for antidiabetic drugs, as well as its role in responding to endogenous compounds such as prostaglandin J2. However, thiazolidinediones (TZDs), the synthetic agonists of the PPARγ are tightly associated with fluid retention and edema, as potentially serious side effects. The epithelial sodium channel (ENaC) represents the rate limiting step for sodium absorption in the renal collecting duct. Consequently, ENaC is a central effector impacting systemic blood volume and pressure. The role of PPARγ agonists on ENaC activity remains controversial. While PPARγ agonists were shown to stimulate ENaC-mediated renal salt absorption, probably via Serum- and Glucocorticoid-Regulated Kinase 1 (SGK1), other studies reported that PPARγ agonist-induced fluid retention is independent of ENaC activity. The current paper provides new insights into the control and function of ENaC and ENaC-mediated sodium transport as well as several other epithelial channels/transporters by PPARs and particularly PPARγ. The potential contribution of arachidonic acid (AA) metabolites in PPAR-dependent mechanisms is also discussed.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to a nuclear hormone receptor superfamily containing three isoforms (alpha, beta/delta, and gamma). The name peroxisome proliferator-activated receptor derives from the ability of the first member of the family identified, PPARα, to respond to various compounds that induce peroxisome proliferation. This function is not shared by other members of the PPAR family. Instead, they have emerged as major regulators of various aspects of lipid metabolism and metabolic control [13]. PPAR-β/δ (NR1C2) is ubiquitously expressed in many tissues, especially in the brain; however, its function has yet to be clearly defined.

This paper will focus on two isoforms: PPARγ and to less extent PPARα. Their role has been increasingly recognized to be important in hypertension, metabolic disorders and cardiovascular diseases. Furthermore nuclear receptors including PPARγ are promising targets for drug development. Functioning as transcription factors they control cellular processes at the level of gene expression. Their modulation of nuclear receptor activity produces selective alterations in downstream gene expression. PPARs regulate gene transcription by two mechanisms: (1) transactivation, a DNA-dependent mechanism, which involves binding to PPAR response elements (PPRE) of target genes and heterodimerization with the retinoid X receptor (RXR); (2) transrepression, a process that may explain the contradictory of actions of PPARs. Transrepression involves interfering with other transcription-factor pathways in a DNA-independent way [1].

Various fatty acids serve as endogenous ligands for PPARs: prostaglandin J2 is an endogenous PPARγ ligand, whereas PPARα is activated by cytokines. After ligand binding, PPARs undergo specific conformational changes that allow for the recruitment of one coactivator protein or more. PPARs function as an obligate heterodimer with RXRs and recognize PPRE located in the promoter region of target genes [4]. In addition, PPAR activators were shown to inhibit the activation of inflammatory response genes by negatively interfering with the nuclear factor-κB (NF-κB), STAT and AP-1 signaling pathways [5]. These characteristics, combined with PPARs involvement in significant diseases, make nuclear receptors a key target for the development of disease-specific therapies.

2. PPARs and Their Role in Hypertension and Fluid Retention

Insulin-sensitizing drugs thiazolidinediones (TZDs) are known as PPARγ-agonists, and hypolipidemic drugs fibrates are known as PPARα ligands. Agonists of PPARγ and PPARα are currently approved for use in treating type 2 diabetes and dyslipidemia, respectively.

PPARα is expressed predominantly in the liver, heart, muscle, and vascular wall. Sato and colleagues generated isoform-specific anti-PPAR antibodies to determine the localization of these proteins in the rat kidney [6]. Regarding PPARα, it was widely expressed along the nephron segments (proximal and distal tubules, the loop of Henle, and medullary collecting ducts) glomeruli, and intima/media of renal vasculatures. Previous studies reported that PPARα expression was mainly localized to the proximal tubules [79]. Based on the prominent distribution of PPARα in the kidney, PPARα is likely to affect renal salt transport. However, it is important to note that tissue expression of all three PPAR isoforms is likely to vary under differing physiological and/or pathological conditions.

Interestingly, studies using PPARα−/− mice have produced conflicting findings in regard to its role in blood pressure regulation [10]. Deletion of PPARα has been shown to significantly increase [11], decrease [12] and have no significant effect [13] on systolic blood pressure compared with wild-type controls. Further studies suggest that PPARα  participates in pressure natriuresis and affects Na+ transport via amiloride- and thiazide-sensitive mechanisms. Despite defective fatty acid oxidation, PPARα null mice are not hypertensive but develop salt-sensitive hypertension [14]. The observation that clofibrate improved pressure natriuresis [15] and PPARα activation inhibited ion transport in the isolated proximal tubules [16], gives credence to the notion that PPARα may be involved in the salutary effects of the kidney. However, a role of PPARα in ENaC-mediated sodium reabsorption is still unclear.

Troglitazone was the first TZD which was approved in January 1997 as a glucose-lowering therapy because it enhances insulin sensitivity in patients with type 2 diabetes [17]. Due to hepatotoxicity, it has since been replaced by PPARγ-agonists rosiglitazone and pioglitazone [1]. However, both rosiglitazone and pioglitazone have been associated with increased development of edema in clinical trials. Non-insulin-dependent diabetes mellitus with associated insulin insensitivity and reactive hyperinsulinemia is often complicated by hypertension. Increased blood pressure could in part be due to volume expansion resulting from improper avid Na+ reabsorption by the kidney. Insulin increases Na+ reabsorption in the distal renal nephron; likely by targeting ENaC localized to the luminal membrane of principal cells. The highest incidence of edema has been reported when TZDs are utilized in combination with insulin.

In addition to peripheral edema, reports have described pulmonary edema and heart failure associated with thiazolidinedione therapy. In all such reports, patients failed to respond to diuretics during use of TZDs. Clinical improvement ensued only after discontinuation of TZD therapy [18, 19]. A water-electrolyte imbalance observed in these patients led researchers to investigate PPARs participation in kidney function. Laboratory studies have demonstrated that rosiglitazone treatment does not affect blood pressure or angiotensin-II (Ang II) production by mesangial cells and plays a renoprotective role in Sprague-Dawley rats [20]. Moreover, TZDs normalized expression of angiotensin converting enzyme-1 in obese Zucker rats as well as lowered blood pressure and angiotensin-II synthesis in spontaneously hypertensive rats on a high-salt diet with glycerol-induced acute renal failure [21, 22].

It has been proposed that TZDs may be useful in the prevention and/or treatment of hypertension, particularly when it is associated with insulin resistance or diabetes mellitus. TZDs attenuate the development of hypertension, normalize cell growth, and improve endothelial dysfunction induced by (Ang II). In addition TZDs prevented upregulation of Ang II type 1 receptors, cell cycle proteins, and proinflammatory mediators [23]. It has been suggested that the apparent hypotensive effects of PPARγ agonists in this model may result from down regulation of the Ang II type 1 receptor [10, 24]. Moreover, PPARγ was identified as an intracellular mediator involved in the upregulation of renin transcription [25]. Using PPARγ-knockdown in juxtaglomerular cells (RC-PPARγfl/fl mice), increased renin production was found even though arterial pressure was indistinguishable in these mice compared to wild-type animals [26].

Mouse models that disrupt PPARγ specifically in the collecting ducts (CDs) in the kidney have been used to evaluate a role of PPARγ in fluid retention. Guan et al. demonstrated that deletion of CD PPARγ decreased renal Na+ avidity and increased plasma aldosterone. Mice treated with TZDs experience early weight gain from increased total body water. Moreover, weight gain was blocked by the diuretic amiloride [27]. Similarly, Zhang et al. found that mice with CD-specific knockout of PPARγ were resistant to the rosiglitazone-induced increase in body weight and plasma volume expansion found in control mice expressing PPARγ in the CD [28]. The role of PPARγ in regulation of sodium transport in the kidney will be further discussed below.

3. PPARs and Arachidonic Acid Metabolites

Natural and synthetic ligands bind to PPARs, resulting in a conformational change and activation of PPAR. The identity of the biological ligands for PPARs remains unresolved and is an area of active investigation. The PGD2 metabolite, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), was the first endogenous ligand for PPARγ to be discovered. Although 15d-PGJ2 is the most potent natural ligand of PPARγ, the extent to which its effects are mediated through PPARγin vivo remains to be determined. It is unlikely that 15d-PGJ2 is present at sufficient levels in vivo to be a biologically significant PPAR ligand. Furthermore, it is possible that ligands for PPARs have different potency and efficacy and may be distinct in different tissues.

The function of PPARs is modified by the precise shape of their ligand-binding domain; which is induced by ligand binding as well as a number of coactivators and corepressor proteins. It is well known that endogenous ligands for the PPARγ include free fatty acids and http://en.wikipedia.org/wiki/Eicosanoid eicosanoids. Furthermore, the localization of CYP4A and PPARγ proteins as well as the inducibility of Cyp4A expression and activity by PPARγ agonists have been determined in the rat kidney [29]. Moreover, the effect of PPARγ agonists on the Cyp4A pathway was recently demonstrated and provided experimental evidence that pioglitazone down regulates Cyp4A leading to sodium retention [30]. Treatment of hypertensive Cyp4a10(-/-) mice with Wyeth 14,643, (a selective PPARα ligand), up-regulated renal Cyp2c44 expression, increased urine epoxyeicosatrienoic acid (EET) concentrations, and normalized the animals systemic blood pressure [31, 32]. Thus, it is possible that eicosanoids and free fatty acids might be involved in PPARs-regulated changes in fluid retention.

Multiple factors are presumed to regulate renal sodium handling including the renin-angiotensin system (RAS), nitric oxide (NO), and prostaglandins. Recent studies have demonstrated that PPARγ ligands enhance NO production through the increased expressions of NO synthase (NOS) in the kidneys of obese rats, thus shifting the sodium balance to increased excretion [33]. In addition, PPARγ is reported to induce cyclooxygenase-2 (COX-2), an enzyme producing PGE2 and PGI2 in several cell lines [34], which also could favor sodium excretion.

Arachidonic acid (AA) is primarily metabolized by cytochrome P-450 (CYP) enzymes to 19- and 20-hydroxyeicosatetraenoic acids (19- and 20-HETE) and EETs (5,6-, 8,9-, 11,12-, and 14,15-EET) and these compounds play critical roles in the regulation of renal, pulmonary and cardiac function [35]. The expression of CYP 4A (CYP4A) isoform was determined in cortical collecting ducts (CCDs) [36]. Similarly, Cyp2C isoforms are expressed in the CCD [3739]. It was previously shown that AA significantly decreases ENaC activity in CCD cells. Adenosine inhibits ENaC activity by stimulation of the A1 adenosine receptor in the CCD and the effect of adenosine is mediated by 11,12-EET [38, 40, 41]. 11,12-EET has also been shown to mediate AA-induced inhibition of 18 pS basolateral K+ channels [42] and activation of BK channels in the apical membrane of the CCD [39]. 20-HETE and EETs have actions on the thick ascending limb (TAL) cells that would decrease sodium reabsorption. 20-HETE production is involved in reducing the activity of the apical 70 pS K+ channels in the medullary TAL (mTAL) [43, 44]. AA inhibits 50 pS K+ channels in the basolateral membrane of the mTAL mainly through CYP-dependent metabolities of AA [45]. Recently it was demonstrated that AA inhibits the 10 pS chloride channel in the basolateral membrane of the mTAL and that the effect is mediated by 20-HETE [46]. Thus, AA and its metabolites are involved in the regulation of various ion channels in the kidney. Moreover, a dysfunctional Cyp4a10 gene causes a type of hypertension that is dietary salt sensitive and associated with alterations in the gating activity of ENaC [31]. The above observations allow the speculation that TZDs might suppress specific AA metabolite production, therefore reducing sodium excretion.

4. PPARs and ENaC

The regulation of sodium reabsorption is one of the most important questions in the area of kidney physiology. ENaC represents the rate limiting step for Na+-reabsorption across many epithelia, including those in the distal nephron, lungs and colon, and as such plays a central role in salt homeostasis and blood pressure control [47, 48]. ENaC-mediated sodium transport plays a pivotal role in homeostasis of epithelial kidney tissues and other organs. Abnormalities in ENaC function have been linked to disorders of total body Na+ homeostasis, blood volume, blood pressure, and lung fluid balance [49, 50]. Despite several reports testing regulation of ENaC by PPARγ, the role of PPARγ to regulate ENaC has not yet been fully resolved and remains controversial. Here, we summarize the current knowledge regarding involvement of PPARs in regulation of this channel.

Guan et al. found that treatment with rosiglitazone and pioglitazone causes body fluid accumulation in C57BL/6J mice within a span of days. Pretreatment of mice with amiloride, a selective inhibitor of ENaC, completely blocked weight gain produced by subsequent treatment with pioglitazone. To establish whether CD PPARγ expression is required for TZD-associated weight gain, mice were generated that selectively lack PPARγ in their CDs. This deletion prevented pioglitazone-induced fluid retention, decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured CDs with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding ENaC γ-subunit) expression through a PPARγ-dependent pathway [27]. Independently, Zhang and colleagues showed that CD-specific deletion of PPARγ blocks TZD-induced fluid retention in mice and that rosiglitazone stimulated sodium transport in primary cultures of CDs cells expressing PPARγ but not in cells lacking this receptor [28]. Plasma volume expansion, decreased urine volume and sodium excretion were also observed in Sprague-Dawley rats treated with TZDs rosiglitazone and farglitazar [51, 52].

It was proposed that PPARγ activators may increase renal Na+ reabsorption by stimulating ENaC and Serum- and Glucocorticoid-Regulated Kinase 1 (SGK1). The CCD is the major segment mediating the sodium-retaining effects of aldosterone, primarily through the upregulation of ENaC activity. The early effect of aldosterone on ENaC-α translocation is believed to be regulated by SGK1; as SGK1 expression is rapidly induced by aldosterone and strongly stimulates ENaC activity [54, 55]. PPARγ is abundant in native CCD [9]. PPARγ is also highly expressed in human renal CCD [56], the A6, M1 and mpkCCDc14 cells [57]. Splice variants of the human PPARγ (PPAR-γ1 and PPAR-γ2) have been identified [58]. It was shown that PPAR-γ1, but not PPAR-γ2, was expressed along the nephron segments predominantly in the cortex [6].

Hong et al. have previously shown that SGK1 activity in a human CCD cell line is stimulated by treatment with PPARγ agonists. These changes are paralleled by an increase in SGK1 mRNA which may be abolished by pretreatment with a specific PPARγ antagonist. An increase in SGK1 mRNA may also lead to increased levels of cell surface ENaCα [56]. PPARγ agonists have been proposed to increase renal Na+ reabsorption by stimulating SGK1 and ENaC [59]. Artunc et al. also have demonstrated that SGK1 contributes to the volume retention during treatment with pioglitazone using mice lacking SGK1 (sgk1–/–); however, SGK1 did not fully account for this effect [54].

Increasing evidence suggest that PPARγ agonists do not directly alter ENaC activity or ENaC-mediated sodium reabsorption. Nofziger et al. first demonstrated that activation of PPARγ with either pioglitazone or the more potent GW7845 does not directly enhance basal or insulin-stimulated Na+ transport via ENaC in the A6, M-1 or mpkCCDc14 cell lines. No change in SGK1 expression levels were found in mpkCCDc14 cells after 18–24 hrs treatment with PPARγ agonists [57]. Similar to this study, we demonstrated no changes or even a slight decrease in basal sodium or insulin-stimulated reabsorption in mpkCCDc14 cells in response to different PPARγ agonists including: pioglitazone, rosiglitazone, troglitazone and 15d-PGJ2. Moreover rosiglitazone has no effect on ENaC current density when the channel was reconstituted in CHO cells [53]. Wilson and colleagues have also recently confirmed our observations that rosiglitazone and pioglitazone had no discernible effect on transepithelial Na+ absorption in unstimulated or insulin-stimulated distal nephron cells and distal airway epithelial cells. Both TZDs also failed to alter cellular SGK1 activity [60].

Furthermore, Vallon and colleagues utilized mice with conditionally inactivated α-ENaC (Scnn1aloxloxCre) in CDs to test the role of ENaC in TZD-induced fluid retention. Interestingly, increased body weight, plasma volume, and fluid content of abdominal fat pads were observed both in control (Scnn1aloxlox) and Scnn1aloxloxCre animals after rosiglitazone treatment. However, the treatment did not significantly alter the renal expression of ENaC subunits or Na-Cl cotransporter (NCC) in both mouse lines [61]. Similar, Khan et al. had earlier also demonstrated that renal cortical abundance of NCC was not significantly changed in obese Zucker rats after rosiglitazone treatment [62]. Vallon et al. proposed that TZDs-induced fluid retention and weight gain are mediated by nonselective cation channels (NSC) in inner medullary CD (IMCD) and ENaC-mediated Na+ reabsorption in CDs is not critical for this effect. According to single-channel data, a TZD diet did not affect ENaC activity in freshly isolated CCDs of wild-type mice [61]. These data strongly argue against a primary and critical role of ENaC in TZD-induced fluid retention. On the other hand, this study does not explain TZD-dependent increase of γ-ENaC mRNA expression [27] or cell surface expression measured with cell surface biotinylation of α-ENaC after 4 hrs and α-ENaC mRNA after 24 hrs treatment with TZDs in human CCD [56]. Furthermore, as proposed by Rubera et al., CD-specific inactivation of α-ENaC does not impair sodium balance [63]. When α-ENaC expression was deleted selectively from the CDs, leaving intact ENaC expression in the renal connecting tubule and nonrenal tissues, the mice were viable and exhibited only a very mild phenotype with little or no inability to maintain fluid homeostasis in the face of salt or water restriction [63].

Our recent findings have shown that two PPARγ antagonists, T0070907 and to a lesser extent GW9662, decrease Na+ reabsorption across mpkCCDc14 principal cells. Furthermore, pretreatment of monolayers with T0070907 diminished the insulin-stimulated sodium transport. Coexpression of PPARγ1 enhances ENaC activity when all three channel subunits and PPARγ1 are reconstituted in CHO cells (Figure 1) [53]. Thus, our data using PPARγ antagonists are consistent with the idea that PPARγ activity is important for maintaining basal and insulin-dependent transepithelial Na+ transport and ENaC activity.

Figure 1
Effect of PPARγ antagonists on amiloride-sensitive current. (a) Time course of decreases in relative Na+ transport in response to PPARγ inhibition with GW9662 (10 μM). mpkCCDc14 cells were serum-starved overnight. PPAR ...

There are no studies showing acute effect of TZDs on ENaC-mediated sodium reabsorption. Thus, most likely TZDs affect epithelial transport through only genomic mechanisms. In transrepression, PPARγ can repress gene transcription by negatively interfering with other signal-transduction pathways, such as NF-κB signaling pathway, in a DNA-binding-independent manner [1]. The RXR is the required heterodimer partner of PPARs. It was previously shown that RXRα mRNA was present predominately in proximal convoluted tubule (PCT) and IMCD, whereas RXRβ was present in all nephron segments examined except mTAL [9]. RXR, which interacts with the PPARs, is activated by 9-cis retinoic acid. When combined as a PPAR:RXR heterodimer, the PPAR ligands and 9-cis retinoic acid act synergistically on PPAR responses. It is still not clear whether TZDs regulate ENaC activity and ENaC-mediated sodium transport in the presence of 9-cis retinoic acid.

To date there are no reports for the involvement of PPARα in regulation of ENaC activity. Our recent investigation surprisingly revealed a suppressive influence of PPARα on amiloride-sensitive current density when coexpressed with ENaC subunits in CHO cells (Figure 2). Figure 2(a) shows overlays of ENaC currents from typical whole cell voltage clamp experiments elicited by standard voltage ramps before and after amiloride (10 μM). Currents are from cells expressing all three mouse ENaC subunits (0.3 μg each) alone or coexpressed with PPARα (1 μg). Whole-cell macroscopic current recordings of ENaC reconstituted in CHO cells were made under voltage-clamp conditions using standard methods [6466]. Co-expression of PPARα together with ENaC significantly decreased amiloride-sensitive current density from 281 ± 50 to 129 ± 26 pA/pF (Figure 2(b)). Although these data provide initial evidence it is not clear how PPARα is involved in regulation of ENaC and ENaC-mediated sodium transport and requires additional investigations.

Figure 2
PPARα inhibits ENaC when overexpressed in CHO cells. (a) Overlays of typical macroscopic current traces before (arrow) and after 10 μM amiloride from voltage-clamped CHO cells transfected with mENaC alone (top) and with PPARα ...

To place these observations in the context with those previously reported by others, our results appear to be most supportive of the idea that ENaC is involved in PPARγ-regulated changes in fluid retention. However, possible mechanisms underlining the regulation of ENaC via PPARγ remain obscure and require additional studies. Furthermore, the potential role of PPARα and RXR in regulation of sodium transport needs to be clarified.

5. Other Targets of PPAR

Several additional studies argue against the notion that TZD-induced edema formation in CCDs is due to direct renal salt and water retention. Consequently, several mechanisms have been proposed. As discussed above, patch-clamp studies in primary mouse IMCD cells detected a NSC that was upregulated by pioglitazone [61]. Moreover, electrophysiological studies of cultured IMCD cells recently revealed that following exposure to rosiglitazone, amiloride-sensitive short-circuit current was unchanged at 24 hrs but was significantly decreased at 48 hrs. Along this line mRNA expression of all three ENaC subunits exhibited a trend of reduction at 24 hrs and a nearly 50% reduction at 48 hrs. Despite ENaC inhibition, transepithelial resistance was significantly reduced, suggesting an alternative route of increased ion transport. However, this effect was blunted in the IMCD cells derived from mice lacking PPARγ. It has been proposed that rosiglitazone-treatment of primary IMCD cell monolayers exhibit increased paracellular Cl flux, and to a lesser extent, paracellular Na+ flux [67].

In addition various epithelial transport proteins may contribute to TZD-induced reabsorption in the nephron. The proximal tubule is known to mediate more than half of total tubular sodium and water reabsorption [68]. Saad and others have recently shown that PPARγ agonists enhance the expression of NHE3 (Na+/H+ exchanger), AQP1 and AQP7 water channels in human proximal tubule cells through SGK1-dependent pathways [69]. Song and colleagues noticed that rosiglitazone increased whole kidney protein abundance of the α-1 subunit of Na+/K+-ATPase, Na-K-2Cl contransporter (NKCC2), NHE3, AQP 2 and 3, and NOS [51].

Several investigations have focused on the role of PPARγ as a regulator of chloride transport through cAMP-regulated chloride channel (cystic fibrosis transmembrane regulator, CFTR). It was shown that PPARγ expression is altered in tissue lacking CFTR. PPARγ expression in cftr-/- mice is downregulated at the RNA and protein levels and its function diminished [70]. These changes may be related to the loss of function of CFTR and may be relevant to the pathogenesis of metabolic abnormalities associated with cystic fibrosis. Recently Nofziger et al. demonstrated that PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cells. The PPARγ agonist-induced downregulation of anion secretion is the result of decreased CFTR expression and suggests a primary role for inhibition of CTRF in the development of water and electrolyte imbalance during PPARγ agonist therapy [7173]. Similar TZD-mediated effects on Cl flux has been demonstrated in mouse intestinal epithelia [74]. PPARγ agonists have been considered for treatment of cystic fibrosis on the basis of their anti-inflammatory activities [75]. Importantly, Harmon and colleagues have recently established that additional parameters, such as metabolites of AA should be considered in the design of clinical trials [76]. Experimental studies have shown that colonic epithelial cells and whole lung tissue from Cftr-deficient mice show a defect in PPARγ function that contributes to a pathological program of gene expression. Lipidomic analysis suggests that this defect results in part from reduced amounts of the endogenous PPARγ-ligand, 15-keto-prostaglandin E2.

6. Conclusions

Here we summarize the current knowledge of PPARγ-dependent regulation of ENaC activity and ENaC-mediated sodium reabsorption. This regulation is clearly not completely understood and requires further studies. Differences in these reported findings may be for example due to the dose and time-course of treatment, species or expression system, and/or the possibility that some studies are examining total protein pools and others mRNA levels. Even in vivo studies have their limitations. Additional studies are required to sort out the exact contribution of PPARγ to ENaC regulation. Figure 3 details a possible model for PPARγ regulation of epithelial transport through ENaC-dependent and independent mechanisms in the collecting duct. Thus, the exact mechanism by which PPARγ agonists induce fluid retention is not completely clear but is likely to be multifactorial. It is undoubted that ENaC is not the sole channel responsible for fluid retention and sodium reabsorption in response to PPARγ agonists. Other channels and transporters such as NSC in IMCD, CFTR, Na-K-ATPase, NHE3, and NKCC are most likely also involved in this process. However, a clear account of these proteins in water-electrolyte homeostasis during TZD therapy is still needed. Furthermore, a role of PPARα agonists and RXR is also unclear and requires additional studies.

Figure 3
Schematic illustration of the proposed role for PPARγ in the renal collecting duct. PPARγ activation by TZDs or endogenous ligands regulate various epithelial channels/transporters including: (1) epithelial Na+ channel (ENaC) either directly ...

Acknowledgments

The authors are grateful to Nevin Mlodik (Medical College of Wisconsin) for critical reading and correcting this paper and Dr. Frank Gonzalez (National Cancer Institute/National Institutes of Health) for providing PPARα construct. This work was supported by the American Heart Association, the American Society of Nephrology and the MCW Research Affair Committee (to Alexander Staruschenko) and Advancing a Healthier Wisconsin and National Institutes of Health grants HL-59699 and DK38226 (to John D. Iming).

References

1. Yki-Järvinen H. Thiazolidinediones. The New England Journal of Medicine. 2004;351(11):1106–1158. [PubMed]
2. Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them? Biochimica et Biophysica Acta. 2007;1771(8):1082–1093. [PubMed]
3. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ Annual Review of Biochemistry. 2008;77:289–312. [PubMed]
4. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Progress in Hormone Research. 2001;56(1):239–263. [PubMed]
5. Chinetti G, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Research. 2000;49(10):497–505. [PubMed]
6. Sato K, Sugawara A, Kudo M, Uruno A, Ito S, Takeuchi K. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertension Research. 2004;27(6):417–425. [PubMed]
7. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 1996;137(1):354–366. [PubMed]
8. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. American Journal of Physiology. 1997;273(6):F1013–F1022. [PubMed]
9. Yang T, Michele DE, Park J, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. American Journal of Physiology. 1999;277(6):F966–F973. [PubMed]
10. Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacology & Therapeutics. 2009;122(3):246–263. [PubMed]
11. Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)α-mediated cardiovascular effects. Mutation Research. 2005;579(1-2):163–171. [PubMed]
12. Guellich A, Damy T, Lecarpentier Y, et al. Role of oxidative stress in cardiac dysfunction of PPARα−/− mice. American Journal of Physiology. 2007;293(1):H93–H102. [PubMed]
13. Loichot C, Jesel L, Tesse A, et al. Deletion of peroxisome proliferator-activated receptor-α induces an alteration of cardiac functions. American Journal of Physiology. 2006;291(1):H161–H166. [PubMed]
14. Obih P, Oyekan A. Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice. Blood Pressure. 2008;17(1):55–63. [PubMed]
15. Alonso-Galicia M, Frohlich B, Roman RJ. Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. Hypertension. 1998;31(1):232–236. [PubMed]
16. Newaz MA, Ranganna K, Oyekan AO. Relationship between PPARα activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacology. 2004;4, article 1 [PMC free article] [PubMed]
17. Horion ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998;21(9):1462–1469. [PubMed]
18. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocrine Practice. 2003;9(5):406–416. [PubMed]
19. Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Research. 2008 Article ID 943614. [PMC free article] [PubMed]
20. Efrati S, Berman S, Ilgiyeav E, Averbukh Z, Weissgarten J. PPAR-γ activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron. 2007;106(4):e107–e112. [PubMed]
21. Song J, Liu H, Ressom HW, Tiwari S, Ecelbarger CM. Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese zucker rats as determined by microarray analysis. Experimental and Clinical Endocrinology and Diabetes. 2008;116(6):315–325. [PubMed]
22. Yousefipour Z, Hercule H, Truong L, Oyekan A, Newaz MA. Ciglitazone, a peroxisome proliferator-activated receptor γ inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure. Journal of Pharmacology and Experimental Therapeutics. 2007;322(2):461–468. [PubMed]
23. Diep QN, Mabrouk ME, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ Circulation. 2002;105(19):2296–2302. [PubMed]
24. Sugawara A, Takeuchi K, Uruno A, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology. 2001;142(7):3125–3134. [PubMed]
25. Todorov VT, Desch M, Schmitt-Nilson N, Todorova A, Kurtz A. Peroxisome proliferator-activated receptor-γ is involved in the control of renin gene expression. Hypertension. 2007;50(5):939–944. [PubMed]
26. Desch M, Schreiber A, Schweda F, et al. Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-γ in juxtaglomerular cells. Hypertension. 2010;55(3):660–666. [PMC free article] [PubMed]
27. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Medicine. 2005;11(8):861–866. [PubMed]
28. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(26):9406–9411. [PubMed]
29. Ishizuka T, Ito O, Tan L, et al. Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertension Research. 2003;26(11):929–936. [PubMed]
30. Yoshioka K, Wakino S, Homma K, et al. Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-γ ligands in ovariectomized obese rats. Obesity. 2008;16(5):965–971. [PubMed]
31. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. Journal of Clinical Investigation. 2006;116(6):1696–1702. [PMC free article] [PubMed]
32. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney International. 2007;72(6):683–689. [PubMed]
33. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension. 2004;43(1):48–56. [PubMed]
34. Bishop-Bailey D, Warner TD. PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-γ antagonist. The FASEBJ Journal. 2003;17(13):1925–1927. [PubMed]
35. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiological Reviews. 2002;82(1):131–185. [PubMed]
36. Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome P-450 4A isoforms along the rat nephron. American Journal of Physiology. 1998;274(2, part 2):F395–F404. [PubMed]
37. Ma J, Qu W, Scarborough PE, et al. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. The Journal of Biological Chemistry. 1999;274(25):17777–17788. [PubMed]
38. Sun P, Lin D-H, Wang T, et al. Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC. American Journal of Physiology. 2006;291(6):F1192–F1200. [PubMed]
39. Sun P, Liu W, Lin D-H, et al. Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct. Journal of the American Society of Nephrology. 2009;20(3):513–523. [PubMed]
40. Wei Y, Lin D-H, Kemp R, et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. Journal of General Physiology. 2004;124(6):719–727. [PMC free article] [PubMed]
41. Wei Y, Sun P, Wang Z, Yang B, Carroll MA, Wang W-H. Adenosine inhibits ENaC via cytochrome P-450 epoxygenase-dependent metabolites of arachidonic acid. American Journal of Physiology. 2006;290(5):F1163–F1168. [PubMed]
42. Wang Z, Wei Y, Falck JR, Atcha KR, Wang W-H. Arachidonic acid inhibits basolateral K channels in the cortical collecting duct via cytochrome P-450 epoxygenase-dependent metabolic pathways. American Journal of Physiology. 2008;294(6):F1441–F1447. [PMC free article] [PubMed]
43. Gu R, Wei Y, Jiang H, Balazy M, Wang W. Role of 20-HETE in mediating the effect of dietary K intake on the apical K channels in the mTAL. American Journal of Physiology. 2001;280(2):F223–F230. [PubMed]
44. Wang W-H, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca2+-induced inhibition of apical K+ channels in the TAL. American Journal of Physiology. 1996;271(1):C103–C111. [PubMed]
45. Gu R-M, Wang W-H. Arachidonic acid inhibits K channels in basolateral membrane of the thick ascending limb. American Journal of Physiology. 2002;283(3):F407–F414. [PubMed]
46. Gu R-M, Yang L, Zhang Y, et al. CYP-omega-hydroxylation-dependent metabolites of arachidonic acid inhibit the basolateral 10 pS chloride channel in the rat thick ascending limb. Kidney International. 2009;76(8):849–856. [PMC free article] [PubMed]
47. Alvarez de la Rosa DG, Canessa CM, Fyfe GK, Zhang P. Structure and regulation of amiloride-sensitive sodium channels. Annual Review of Physiology. 2000;62:573–594. [PubMed]
48. Garty H, Palmer LG. Epithelial sodium channels: function, structure and regulation. Physiological Reviews. 1997;77(2):359–396. [PubMed]
49. Schild L. The epithelial sodium channel: from molecule to disease. Reviews of Physiology, Biochemistry and Pharmacology. 2004;151:93–107. [PubMed]
50. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. Journal of the American Society of Nephrology. 2008;19(10):1845–1854. [PubMed]
51. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. Journal of Pharmacology and Experimental Therapeutics. 2004;308(2):426–433. [PubMed]
52. Chen L, Yang B, McNulty JA, et al. GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats. Journal of Pharmacology and Experimental Therapeutics. 2005;312(2):718–725. [PubMed]
53. Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A. Peroxisome proliferator-activated receptor γ antagonists decrease Na+ transport via the epithelial Na+ channel. Molecular Pharmacology. 2009;76(6):1333–1340. [PubMed]
54. Artunc F, Sandulache D, Nasir O, et al. Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARγ agonist pioglitazone. Pflugers Archiv European Journal of Physiology. 2008;456(2):425–436. [PubMed]
55. Chen S-Y, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(5):2514–2519. [PubMed]
56. Hong G, Lockhart A, Davis B, et al. PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells. The FASEBJ Journal. 2003;17(13):1966–1968. [PubMed]
57. Nofziger C, Chen L, Shane MA, Smith CD, Brown KK, Blazer-Yost BL. PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel. Pflugers Archiv European Journal of Physiology. 2005;451(3):445–453. [PubMed]
58. Fajas L, Auboeuf D, Raspé E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. The Journal of Biological Chemistry. 1997;272(30):18779–18789. [PubMed]
59. Vallon V, Lang F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Current Opinion in Nephrology and Hypertension. 2005;14(1):59–66. [PubMed]
60. Wilson SM, Mansley MK, Getty J, Husband EM, Inglis SK, Hansen M. Effects of peroxisome proliferator-activated receptor g agonists on Na+ transport and activity of the kinase sgk1 in epithelial cells from lung and kidney. British Journal of Pharmacology. 2010;159(3):678–688. [PMC free article] [PubMed]
61. Vallon V, Hummler E, Rieg T, et al. Thiazolidinedione-induced fluid retention is independent of collecting duct αENaC activity. Journal of the American Society of Nephrology. 2009;20(4):721–729. [PubMed]
62. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. American Journal of Physiology. 2005;289(2):F442–F450. [PubMed]
63. Rubera I, Loffing J, Palmer LG, et al. Collecting duct-specific gene inactivation of αENaC in the mouse kidney does not impair sodium and potassium balance. Journal of Clinical Investigation. 2003;112(4):554–565. [PMC free article] [PubMed]
64. Karpushev AV, Levchenko V, Pavlov TS, et al. Regulation of ENaC expression at the cell surface by Rab11. Biochemical and Biophysical Research Communications. 2008;377(2):521–525. [PMC free article] [PubMed]
65. Staruschenko A, Patel P, Tong Q, Medina JL, Stockand JD. Ras activates the epithelial Na+ channel through phosphoinositide 3-OH kinase signaling. The Journal of Biological Chemistry. 2004;279(36):37771–37778. [PubMed]
66. Staruschenko A, Booth RE, Pochynyuk O, Stockand JD, Tong Q. Functional reconstitution of the human epithelial Na+ channel in a mammalian expression system. Methods in Molecular Biology. 2006;337:3–13. [PubMed]
67. Soodvilai S, Aoyagi K, Yang T. PPARgamma stimulates paracellular transport and inhibits ENaC in primary inner medullary collecting duct cells. Journal of the American Society of Nephrology. 2009;20:p. 123A.
68. Panchapakesan U, Pollock C, Saad S. Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology. 2009;14(3):298–301. [PubMed]
69. Saad S, Agapiou DJ, Chen X-M, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-γ agonists in human proximal tubule cells. Nephrology Dialysis Transplantation. 2009;24(4):1130–1141. [PubMed]
70. Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor γ in CFTR−/− mice. Journal of Cellular Physiology. 2004;200(2):235–244. [PubMed]
71. Nofziger C, Brown KK, Smith CD, et al. PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. American Journal of Physiology. 2009;297(1):F55–F62. [PubMed]
72. Nofziger C, Blazer-Yost BL. PPARγ agonists, modulation of ion transporters, and fluid retention. Journal of the American Society of Nephrology. 2009;20(12):2481–2483. [PubMed]
73. Blazer-Yost BL. PPARγ agonists: blood pressure and edema. PPAR Research. 2010 Article ID 785369. [PMC free article] [PubMed]
74. Bajwa PJ, Lee JW, Straus DS, Lytle C. Activation of PPARγ by rosiglitazone attenuates intestinal Cl secretion. American Journal of Physiology. 2009;297(1):G82–G89. [PubMed]
75. Nichols DP, Konstan MW, Chmiel JF. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clinical Reviews in Allergy and Immunology. 2008;35(3):135–153. [PubMed]
76. Harmon GS, Dumlao DS, Ng DT, et al. Pharmacological correction of a defect in PPAR-α signaling ameliorates disease severity in Cftr-deficient mice. Nature Medicine. 2010;16(3):313–318. [PMC free article] [PubMed]

Articles from PPAR Research are provided here courtesy of Hindawi Publishing Corporation